Cover Image
市場調查報告書

貝塞特氏症候群:開發中產品分析

Behcet Disease - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361617
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
貝塞特氏症候群:開發中產品分析 Behcet Disease - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 70 Pages
簡介

本報告提供貝塞特氏症候群的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

貝塞特氏症候群概要

治療藥的開發

  • 開發中產品的概要

貝塞特氏症候群:企業開發中的治療藥

貝塞特氏症候群:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

貝塞特氏症候群:企業開發中的產品

貝塞特氏症候群的治療藥開發企業

  • AbbVie Inc.
  • Celgene Corporation
  • Delenex Therapeutics AG
  • Genor BioPharma Co., Ltd.
  • HanAll Biopharma Co., Ltd.
  • Mabion SA
  • Mycenax Biotech Inc.
  • R-Pharm

貝塞特氏症候群:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

貝塞特氏症候群:最近的開發平台趨勢

貝塞特氏症候群:暫停中的計劃

貝塞特氏症候群:開發中止的產品

貝塞特氏症候群:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8113IDB

Summary

Global Markets Direct's, 'Behcet Disease - Pipeline Review, H1 2016', provides an overview of the Behcet Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Behcet Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Behcet Disease
  • The report reviews pipeline therapeutics for Behcet Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Behcet Disease therapeutics and enlists all their major and minor projects
  • The report assesses Behcet Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Behcet Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Behcet Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Behcet Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Behcet Disease Overview
  • Therapeutics Development
    • Pipeline Products for Behcet Disease - Overview
  • Behcet Disease - Therapeutics under Development by Companies
  • Behcet Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Behcet Disease - Products under Development by Companies
  • Behcet Disease - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Celgene Corporation
    • Delenex Therapeutics AG
    • Genor BioPharma Co., Ltd.
    • HanAll Biopharma Co., Ltd.
    • Mabion SA
    • Mycenax Biotech Inc.
    • R-Pharm
  • Behcet Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • adalimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • apremilast - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HL-143 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • infliximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RPH-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Behcet Disease - Recent Pipeline Updates
  • Behcet Disease - Dormant Projects
  • Behcet Disease - Discontinued Products
  • Behcet Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir
      • Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet
      • Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine
      • Apr 14, 2015: Delenex Announces New Clinical Data
      • Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR
      • May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet's Disease For Humira Pre-filled Syringe In Japan
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Behcet Disease, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Behcet Disease - Pipeline by AbbVie Inc., H1 2016
  • Behcet Disease - Pipeline by Celgene Corporation, H1 2016
  • Behcet Disease - Pipeline by Delenex Therapeutics AG, H1 2016
  • Behcet Disease - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Behcet Disease - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Behcet Disease - Pipeline by Mabion SA, H1 2016
  • Behcet Disease - Pipeline by Mycenax Biotech Inc., H1 2016
  • Behcet Disease - Pipeline by R-Pharm, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Behcet Disease Therapeutics - Recent Pipeline Updates, H1 2016
  • Behcet Disease - Dormant Projects, H1 2016
  • Behcet Disease - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Behcet Disease, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top